Technology
Genpact Reports Full Year and Fourth Quarter 2024 Results
Published
2 years agoon
By
2024 Net Revenues of $4.77 billion, Up 6.5% (6.7% constant currency)1,2
2024 Data-Tech-AI Net Revenues of $2.23 billion, Up 6.9%1,2,3,4
2024 Digital Operations Net Revenues of $2.53 billion, Up 6.1% (6.5% constant currency)1,4
2024 Diluted EPS of $2.85, Down 16%; Adjusted Diluted EPS of $3.28, Up 10%5,6
Increases Quarterly Dividend by 11% and Share Repurchase Authorization by $500 million
NEW YORK, Feb. 6, 2025 /PRNewswire/ — Genpact Limited (NYSE: G), a global advanced technology services and solutions company, today announced financial results for the fourth quarter and full year ended December 31, 2024.
“We delivered another strong quarter to close out what has been an outstanding year for Genpact. Q4 revenue grew 9% with Data-Tech-AI up 12%, driving accelerating revenue growth. For the full year, revenue grew 6.5%, with adjusted EPS growth of 10%, consistent with our long-term objective of growing adjusted EPS faster than revenue. We also delivered record new bookings of $5.7 billion, up 15%, building on exceptionally strong new bookings in 2023,” said Balkrishan “BK” Kalra, Genpact’s President and CEO. “Looking ahead, we are incredibly excited about the future as we accelerate the pace of innovation and change at Genpact. Building on our industry-specific domain expertise, our investment in Data, AI and Agentic Solutions is positioning us as a clear leader in AI-driven transformation and driving superior value for our clients.”
Key Financial Highlights – Full Year 2024
Net revenues were $4.77 billion, up 6.5% year-over-year on an as reported basis, and 6.7% on a constant currency basis.1,2Data-Tech-AI net revenues were $2.23 billion, up 6.9% year-over-year, both on an as reported and constant currency basis,1,2,4 representing 47% of total revenue.Digital Operations net revenues were $2.53 billion, up 6.1% year-over-year on an as reported basis, and 6.5% on a constant currency basis,1,4 representing 53% of total revenue.Gross profit was $1.69 billion, up 8% year-over-year, with a corresponding margin of 35.5%.Net income was $514 million, down 19% year-over-year, with a corresponding margin of 10.8%.6Income from operations was $702 million, up 11% year-over-year, with a corresponding margin of 14.7%.Adjusted income from operations was $814 million, up 7% year-over-year, with a corresponding margin of 17.1%.6,7Diluted earnings per share was $2.85, down 16% year-over-year.6Adjusted diluted earnings per share was $3.28, up 10% year-over-year.5,6 New bookings were approximately $5.7 billion, up 15% year-over-year.8Cash generated from operations was $615 million, up 25% year-over-year.Genpact repurchased approximately 7 million of its common shares during the year for total consideration of approximately $253 million at an average price per share of $38.31.
Key Financial Highlights – Fourth Quarter 2024
Net revenues were $1.25 billion, up 8.9% year-over-year on an as reported basis and 8.7% on a constant currency basis.1Data-Tech-AI net revenues were $595 million, up 11.9% year-over-year on an as reported basis, and 11.7% on a constant currency basis,1,4 representing 48% of total revenue.Digital Operations net revenues were $654 million, up 6.4% year-over-year on an as reported and 6.1% on a constant currency basis,1,4 representing 52% of total revenue.Gross profit was $446 million, up 9% year-over-year, with a corresponding margin of 35.7%.Net income was $142 million, down 51% year-over-year, with a corresponding margin of 11.4%.6Income from operations was $190 million, up 17% year-over-year, with a corresponding margin of 15.2%.Adjusted income from operations was $221 million, up 9% year-over-year, with a corresponding margin of 17.7%.6,7Diluted earnings per share was $0.79, down 50% year-over-year.6Adjusted diluted earnings per share was $0.91, up 11% year-over-year.5,6Cash generated from operations was $203 million, compared to $192 million in the fourth quarter of 2023.Genpact repurchased approximately 2 million of its common shares during the quarter for total consideration of approximately $85 million at an average price per share of $45.41.
Capital Allocation
Genpact’s Board of Directors declared a quarterly cash dividend for the first quarter of 2025 of $0.17 per common share, an 11% increase, payable on March 26, 2025 to shareholders of record as of the close of business on March 11, 2025, and approved a $500 million increase to the Company’s existing share repurchase authorization. The newly approved quarterly dividend represents a planned annual dividend of $0.68 per common share, increased from $0.61 per common share in 2024.
Outlook
Genpact’s outlook for the full year 2025 is as follows:
Net revenues in the range of $5.029 billion to $5.125 billion, representing year-over-year growth of approximately 5.5% to 7.5% as reported, or 6.2% to 8.2% on a constant currency basis.1Data-Tech-AI net revenues growth of approximately 6.2% year-over-year and Digital Operations net revenues growth of approximately 6.8% year-over-year as reported at the midpoint of the range.Data-Tech-AI net revenues growth of approximately 6.4% year-over-year and Digital Operations net revenues growth of approximately 7.9% year-over-year on a constant currency basis1 at the midpoint of the range.Gross margin of approximately 36.0%.Adjusted income from operations margin9 of approximately 17.3%.Adjusted diluted EPS10 in the range of $3.52 to $3.59.
Genpact’s outlook for the first quarter of 2025 is as follows:
Net revenues in the range of $1.202 billion to $1.213 billion, representing year-over-year growth of approximately 6.2% to 7.2% as reported, or 7.1% to 8.1% on a constant currency basis.1Data-Tech-AI net revenues growth of approximately 9.8% year-over-year and Digital Operations net revenues growth of approximately 4.1% year-over-year as reported at the midpoint of the range.Data-Tech-AI net revenues growth of approximately 10.0% year-over-year and Digital Operations net revenues growth of approximately 5.4% year-over-year on a constant currency basis1 at the midpoint of the range.Gross margin of approximately 35.0%.Adjusted income from operations margin9 of approximately 16.5%.Adjusted diluted EPS10 in the range of $0.79 to $0.80.
Our outlook for the first quarter and full year 2025 reflects foreign currency exchange rates as of January 30, 2025.
1 Revenue growth on a constant currency basis is a non-GAAP measure and is calculated by restating current-period activity using the prior fiscal period’s foreign currency exchange rates adjusted for hedging gains/losses in such period.
2 Net revenues and Data-Tech-AI net revenues for the full year 2023 include $0.5 million of revenue associated with a business classified as held for sale.
3 Both on an as reported and constant currency basis.
4 Genpact updated the classification of certain revenues from Digital Operations to Data-Tech-AI in the quarter ended March 31, 2024 to more accurately reflect the nature of, and mode of delivery for, the services provided, which have evolved over time. As a result, the revenue from Digital Operations and Data-Tech-AI for the full year 2023 originally reported was $2.48 billion and $1.99 billion, respectively, which is $2.39 billion and $2.09 billion, respectively, in accordance with the updated classification. The numbers presented in this release for Data-Tech-AI net revenues and Digital Operations net revenues may not add up precisely to the total net revenues provided due to rounding.
5 Adjusted diluted earnings per share is a non-GAAP measure. A reconciliation of GAAP diluted earnings per share to adjusted diluted earnings per share is attached to this release.
6 During the quarter and full year ended December 31, 2023, Genpact completed an intercompany transfer of certain intellectual property rights from non-US to US wholly-owned subsidiaries, which resulted in a non-recurring tax benefit of $170 million. Net income and diluted earnings per share for the quarter and full year ended December 31, 2023 included this benefit. This benefit was excluded from adjusted diluted earnings per share and adjusted income from operations for the quarter and year ended December 31, 2023.
7 Adjusted income from operations and adjusted income from operations margin are non-GAAP measures. Reconciliations of each of GAAP income from operations and GAAP net income to adjusted income from operations and GAAP income from operations margin and GAAP net income margin to adjusted income from operations margin are attached to this release. Adjusted income from operations margin for the full year 2023 was derived by adjusting total revenue to exclude $0.5 million of revenue associated with a business previously classified as held for sale.
8 New bookings, an operating measure, represents the total contract value of new contracts and certain renewals, extensions and changes to existing contracts. Regular renewals of contracts with no change in scope are not counted as new bookings. Prior to 2024, new bookings of contracts with longer than five-year terms were limited to the total contract value of the initial five-year term. In 2024, Genpact updated its definition of new bookings to eliminate the five-year limitation. New bookings as reported for the full year 2023 were $4.9 billion and would have been $5.0 billion in accordance with the new definition. New bookings for the full year 2024 as reported are $5.7 billion and would have been $5.4 billion in accordance with the prior definition.
9 Adjusted income from operations margin is a non-GAAP measure. A reconciliation of the outlook for each of GAAP income from operations margin and GAAP net income margin to adjusted income from operations margin is attached to this release.
10 Adjusted diluted earnings per share is a non-GAAP measure. A reconciliation of the outlook for GAAP diluted earnings per share to adjusted diluted earnings per share is attached to this release.
Conference Call to Discuss Financial Results
Genpact’s management will host a conference call on February 6, 2025, at 5:00 PM ET to discuss the company’s performance for the fourth quarter and full year ended December 31, 2024. Participants are encouraged to register here to receive a dial-in number and unique PIN for seamless access. It is recommended to join 10 minutes before the call starts, although registration and dial-in will be available at any time. A live webcast will be available on the Genpact Investor Relations website. For those unable to attend the live call, an archived replay and transcript will be available on the website shortly after the call.
About Genpact
Genpact (NYSE: G) is a global professional services and solutions firm delivering outcomes that shape the future. Our 125,000+ people across 30+ countries are driven by our innate curiosity, entrepreneurial agility, and desire to create lasting value for clients. Powered by our purpose – the relentless pursuit of a world that works better for people – we serve and transform leading enterprises, including the Fortune Global 500, with our deep business and industry knowledge, digital operations services, and expertise in data, technology, and AI.
Safe Harbor
This press release contains certain statements concerning our future growth prospects, including our outlook for 2025, financial results and other forward-looking statements, as defined in the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those in such forward-looking statements. These risks, uncertainties, and other factors include but are not limited to general economic conditions, any deterioration in the global economic environment and its impact on our clients, our ability to develop and successfully execute our business strategies, technological innovation, including AI technology and future uses of agentic AI, generative AI and large language models, and our ability to invest in new technologies and adapt to industry developments at sufficient speed and scale, our ability to effectively price our services and maintain pricing and employee utilization rates, general inflationary pressures and our ability to share increased costs with our clients, wage increases in locations in which we have operations, our ability to attract and retain skilled professionals, our ability to protect our and our clients’ data from security incidents or cyberattacks, the economic and other impacts of geopolitical conflicts and any related sanctions and other measures that have been or may be implemented or imposed in response thereto, as well as any potential expansion or escalation of existing conflicts or economic disruption beyond their current scope, a slowdown in the economies and sectors in which our clients operate, a slowdown in the sectors in which we operate, the risks and uncertainties arising from our past and future acquisitions, our ability to convert bookings to revenues, our ability to manage growth, factors which may impact our cost advantage, changes in tax rates and tax legislation and other laws and regulations, our ability to effectively execute our tax planning strategies, risks and uncertainties regarding fluctuations in our earnings, foreign currency fluctuations, political, economic or business conditions in countries in which we operate, as well as other risks detailed in our reports filed with the U.S. Securities and Exchange Commission, including Genpact’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These filings are available at www.sec.gov. Genpact may from time to time make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. Although Genpact believes that these forward-looking statements are based on reasonable assumptions, you are cautioned not to put undue reliance on these forward-looking statements, which reflect management’s current analysis of future events and should not be relied upon as representing management’s expectations or beliefs as of any date subsequent to the time they are made. Genpact undertakes no obligation to update any forward-looking statements that may be made from time to time by or on behalf of Genpact.
Contacts
Investors
Tyra Whelton
+1 (908) 418-2995
Media
Alexia Taxiarchos
+1 (617) 259-8172
GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Balance Sheets
(Unaudited)
(In thousands, except per share data and share count)
As of December 31, 2023
As of December 31, 2024
Assets
Current assets
Cash and cash equivalents
$ 583,670
$ 648,246
Short-term investments
—
23,359
Accounts receivable, net of allowance for credit losses of $18,278
and $12,094 as of December 31, 2023 and 2024, respectively
1,116,273
1,198,606
Prepaid expenses and other current assets
191,566
209,893
Total current assets
$ 1,891,509
$ 2,080,104
Property, plant and equipment, net
189,803
207,943
Operating lease right-of-use assets
186,167
182,190
Deferred tax assets
298,921
269,476
Intangible assets, net
53,028
26,950
Goodwill
1,683,782
1,669,769
Contract cost assets
202,543
200,900
Other assets, net of allowance for credit losses of $4,096 and $7,320 as
of December 31, 2023 and December 31, 2024, respectively
299,960
349,821
Total assets
$ 4,805,713
$ 4,987,153
Liabilities and equity
Current liabilities
Short-term borrowings
$ 10,000
$ —
Current portion of long-term debt
432,242
26,173
Accounts payable
27,739
36,469
Income taxes payable
38,458
35,431
Accrued expenses and other current liabilities
759,180
812,994
Operating leases liability
50,313
52,672
Total current liabilities
$ 1,317,932
$ 963,739
Long-term debt, less current portion
824,720
1,195,267
Operating leases liability
168,015
153,587
Deferred tax liabilities
11,706
15,908
Other liabilities
234,948
269,041
Total liabilities
$ 2,557,321
$ 2,597,542
Shareholders’ equity
Preferred shares, $0.01 par value, 250,000,000 authorized, none issued
—
—
Common shares, $0.01 par value, 500,000,000 authorized, 179,494,132
and 174,661,953, issued and outstanding as of December 31, 2023 and
2024, respectively
1,789
1,740
Additional paid-in capital
1,883,944
1,945,261
Retained earnings
1,085,209
1,236,696
Accumulated other comprehensive income (loss)
(722,550)
(794,086)
Total equity
$ 2,248,392
$ 2,389,611
Total liabilities and equity
$ 4,805,713
$ 4,987,153
GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Income
(Unaudited)
(In thousands, except per share data and share count)
Three months ended December 31,
2022
2023
2024
Net revenues
$ 1,102,545
$ 1,146,253
$ 1,248,741
Cost of revenue
717,337
738,699
802,969
Gross profit
$ 385,208
$ 407,554
$ 445,772
Operating expenses:
Selling, general and administrative expenses
236,557
237,419
249,157
Amortization of acquired intangible assets
9,862
7,454
6,496
Other operating (income) expense, net
11,038
(51)
(55)
Income from operations
$ 127,751
$ 162,732
$ 190,174
Foreign exchange gains (losses), net
6,080
576
(1,487)
Interest income (expense), net
(15,513)
(12,915)
(11,047)
Other income (expense), net
4,799
8,081
4,908
Income before income tax expense
$ 123,117
$ 158,474
$ 182,548
Income tax expense/(benefit)
33,405
(132,835)
40,633
Net income
$ 89,712
$ 291,309
$ 141,915
Earnings per common share
Basic
$ 0.49
$ 1.61
$ 0.81
Diluted
$ 0.48
$ 1.59
$ 0.79
Weighted average number of common shares used in computing
earnings per common share
Basic
183,371,581
180,956,638
175,880,251
Diluted
187,525,698
183,354,187
179,183,557
GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Income
(Unaudited)
(In thousands, except per share data and share count)
Year ended December 31,
2022
2023
2024
Net revenues
$ 4,371,172
$ 4,476,888
$ 4,767,139
Cost of revenue
2,834,774
2,906,223
3,077,073
Gross profit
$ 1,536,398
$ 1,570,665
$ 1,690,066
Operating expenses:
Selling, general and administrative expenses
938,385
913,061
967,145
Amortization of acquired intangible assets
42,667
31,463
26,476
Other operating (income) expense, net
53,195
(4,716)
(5,616)
Income from operations
$ 502,151
$ 630,857
$ 702,061
Foreign exchange gains (losses), net
15,392
4,274
2,937
Interest income (expense), net
(52,204)
(47,935)
(47,214)
Other income (expense), net
(103)
15,028
19,036
Income before income tax expense
$ 465,236
$ 602,224
$ 676,820
Income tax expense/(benefit)
111,832
(29,031)
163,150
Net income
$ 353,404
$ 631,255
$ 513,670
Earnings per common share
Basic
$ 1.92
$ 3.46
$ 2.88
Diluted
$ 1.88
$ 3.41
$ 2.85
Weighted average number of common shares used in computing
earnings per common share
Basic
184,184,930
182,345,548
178,385,972
Diluted
188,087,240
185,141,843
180,436,900
GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
Year ended December 31,
2022
2023
2024
Operating activities
Net income
$ 353,404
$ 631,255
$ 513,670
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
86,849
72,530
69,778
Amortization of debt issuance costs (including loss on extinguishment of debt)
2,376
1,967
2,412
Amortization of acquired intangible assets
42,667
31,463
26,476
Write-down of intangible assets and property, plant and equipment
1,377
—
—
Impairment charge on assets classified as held for sale
32,575
—
—
Loss on sale of business classified as held for sale
—
802
—
Write-down of operating lease right-of-use assets and other assets
20,307
—
—
Allowance for credit losses
1,583
3,979
13,806
Unrealized loss/(gain) on revaluation of foreign currency asset/liability
525
(1,061)
(11,354)
Stock-based compensation expense
77,373
88,576
66,383
Deferred tax expense (benefit)
(29,151)
(157,932)
36,610
Others, net
863
1,477
(2,179)
Change in operating assets and liabilities:
(Increase) in accounts receivable
(112,341)
(130,791)
(96,555)
(Increase) decrease in prepaid expenses, other current assets, contract cost assets,
operating lease right-of-use assets and other assets
3,822
(39,075)
(73,512)
Increase (decrease) in accounts payable
14,185
(8,215)
8,733
Increase (decrease) in accrued expenses, other current liabilities, operating lease
liabilities and other liability
(54,329)
1,862
63,340
Increase (decrease) in income taxes payable
1,585
(6,025)
(2,184)
Net cash provided by operating activities
$ 443,670
$ 490,812
$ 615,424
Investing activities
Purchase of property, plant and equipment
(50,614)
(55,421)
(82,766)
Payment for internally generated intangible assets (including intangibles under development)
(3,775)
(3,356)
(2,469)
Purchase of short term investments
—
—
—
(23,359)
Proceeds from sale of property, plant and equipment and intangible assets
60
25
2,635
Payment for business acquisitions, net of cash acquired
(33)
(682)
—
Proceeds from / (payment) for divestiture of business
17,769
(19,510)
—
Net cash used for investing activities
$ (36,593)
$ (78,944)
$ (105,959)
Financing activities
Repayment of finance lease obligations
(12,810)
(12,165)
(11,358)
Payment of debt issuance costs
(3,045)
—
(4,165)
Proceeds from long-term debt
239,130
—
400,000
Repayment of long-term debt
(620,130)
(19,875)
(433,125)
Proceeds from short-term borrowings
261,000
148,000
50,000
Repayment of short-term borrowings
(110,000)
(289,000)
(60,000)
Proceeds from issuance of common shares under stock-based compensation plans
27,751
39,485
17,215
Payment for net settlement of stock-based awards
(44,942)
(21,529)
(22,278)
Payment of earn-out consideration
(2,437)
(2,399)
—
Dividend paid
(91,837)
(100,014)
(108,466)
Payment for stock repurchased and retired (including expenses related to stock repurchased)
(214,082)
(225,499)
(252,671)
Net cash used for financing activities
$ (571,402)
$ (482,996)
$ (424,848)
Effect of exchange rate changes
(88,368)
8,033
(20,041)
Net increase (decrease) in cash and cash equivalents
(164,325)
(71,128)
84,617
Cash and cash equivalents at the beginning of the period
899,458
646,765
583,670
Cash and cash equivalents at the end of the period
$ 646,765
$ 583,670
$ 648,246
Supplementary information
Cash paid during the period for interest (including interest rate swaps)
$ 51,147
$ 47,989
$ 68,913
Cash paid during the period for income taxes, net of refunds
$ 145,979
$ 156,733
$ 113,629
Property, plant and equipment acquired under finance lease obligations
$ 7,078
$ 2,459
$ 11,483
Non-GAAP Financial Measures
To supplement the consolidated financial statements presented in accordance with GAAP, this press release includes the following non-GAAP financial measures:
Adjusted income from operations; Adjusted income from operations margin;Adjusted diluted earnings per share; and Revenue growth on a constant currency basis.
These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and may be different from non-GAAP financial measures used by other companies. Accordingly, these non-GAAP financial measures, the financial statements prepared in accordance with GAAP and the reconciliations of Genpact’s GAAP financial statements to such non-GAAP financial measures should be carefully evaluated.
Given Genpact’s acquisitions of varying scale and size, and the difficulty in predicting expenses relating to acquisitions and the amortization of acquired intangibles thereof, since July 2012 Genpact’s management has used financial statements that exclude all acquisition-related expenses and amortization of acquired intangibles for its internal management reporting, budgeting and decision-making purposes, including comparing Genpact’s operating results to those of its competitors. For the same reasons, since April 2016, Genpact’s management has excluded the impairment of acquired intangible assets from the financial statements it uses for internal management purposes. Acquisition-related expenses are excluded in the period in which an acquisition is consummated. Genpact’s management also uses financial statements that exclude stock-based compensation expense. Because of varying available valuation methodologies, subjective assumptions and the variety of award types that companies can use when adopting ASC 718 “Compensation-Stock Compensation,” Genpact’s management believes that providing non-GAAP financial measures that exclude such expenses allows investors to make additional comparisons between Genpact’s operating results and those of other companies.
During the second quarter of 2022, Genpact approved a plan to divest a business that was no longer deemed strategic. Given the specialized nature of this business, we anticipated completing a transaction within twelve months after the end of the second quarter of 2022, and therefore, we classified the revenues and expenses related to this business as held for sale with effect from April 1, 2022. During the first quarter of 2023, the Company consummated this transaction and recorded a loss on the sale of the business. During the second quarter of 2023, the Company terminated a lease for office property which was fully impaired as part of a restructuring in the second quarter of 2022 and recorded a gain on such lease termination as restructuring income in the second quarter of 2023. During the fourth quarter of 2023, Genpact completed an intercompany transfer of certain intellectual property rights from non-US to US wholly-owned subsidiaries, which resulted in a non-recurring tax benefit of $170 million. Genpact’s management believes that excluding the loss on the sale of the business previously classified as held for sale, the revenues and expenses associated with such business, the gain on the lease termination and the non-recurring tax benefit on the transfer of intellectual property rights in calculating its non-GAAP financial measures provides useful information to both management and investors regarding the Company’s financial performance and underlying business trends. Additionally, in its calculations of non-GAAP financial measures, Genpact’s management has adjusted foreign exchange gains and losses, interest income and expense and income tax expenses from GAAP net income, and other income and expenses, and certain gains from GAAP income from operations, because management believes that the Company’s results after taking into account these adjustments more accurately reflect the Company’s ongoing operations. In its calculations of adjusted diluted earnings per share, Genpact’s management adds back stock-based compensation expense, amortization and impairment of acquired intangible assets, and acquisition-related expenses along with the related tax impact of other adjustments and excludes the non-recurring tax benefit on the transfer of intellectual property rights from GAAP diluted earnings per share. For the purpose of calculating adjusted diluted earnings per share, the combined current and deferred tax effect is determined by multiplying each pre-tax adjustment by the applicable statutory income tax rate.
Genpact’s management provides information about revenues on a constant currency basis so that the revenues may be viewed without the impact of foreign currency exchange rate fluctuations compared to prior fiscal periods, thereby facilitating period-to-period comparisons of the Company’s true business performance. Revenue growth on a constant currency basis is calculated by restating current-period activity using the prior fiscal period’s foreign currency exchange rates adjusted for hedging gains/losses in such period.
Accordingly, Genpact believes that the presentation of adjusted income from operations, adjusted income from operations margin, adjusted diluted earnings per share and revenue growth on a constant currency basis, when read in conjunction with the Company’s reported results, can provide useful supplemental information to investors and management regarding financial and business trends relating to its financial condition and results of operations.
A limitation of using adjusted income from operations and adjusted income from operations margin versus income from operations, income from operations margin, net income and net income margin calculated in accordance with GAAP is that these non-GAAP financial measures exclude certain recurring costs and certain other charges, namely stock-based compensation expense and amortization and impairment of acquired intangible assets. Management compensates for this limitation by providing specific information on the GAAP amounts excluded from adjusted income from operations and adjusted income from operations margin.
The following tables show the reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures for the three months and years ended December 31, 2023 and 2024:
Reconciliation of Net Income/Margin to Adjusted Income from Operations/Margin
(In thousands)
Three months ended
December 31,
Year ended
December 31,
2023
2024
2023
2024
Net income
$ 291,309
$ 141,915
$ 631,255
$ 513,670
Foreign exchange (gains) losses, net
(576)
1,487
(4,274)
(2,937)
Interest (income) expense, net
12,915
11,047
47,935
47,214
Income tax expense /(benefit)
(132,835)
40,633
(29,031)
163,150
Stock-based compensation expense
24,726
19,107
88,576
66,383
Amortization and impairment of acquired intangible assets
7,453
6,493
31,348
26,456
Restructuring (income) expense
—
—
(4,874)
—
Operating loss from the business classified as held for sale
—
—
1,201
—
Loss on the sale of business classified as held for sale
—
—
802
—
Adjusted income from operations
$ 202,992
$ 220,682
$ 762,938
$ 813,936
Net income margin
25.4 %
11.4 %
14.1 %
10.8 %
Adjusted income from operations margin
17.7 %
17.7 %
17.0 %
17.1 %
Reconciliation of Income from Operations/Margin to Adjusted Income from Operations/Margin
(In thousands)
Three months ended
December 31,
Year ended
December 31,
2023
2024
2023
2024
Income from operations
$ 162,732
$ 190,174
$ 630,857
$ 702,061
Stock-based compensation expense
24,726
19,107
88,576
66,383
Amortization and impairment of acquired intangible assets
7,453
6,493
31,348
26,456
Other income (expense), net
8,081
4,908
15,028
19,036
Restructuring (income) expense
—
—
(4,874)
—
Operating loss from the business classified as held for sale
—
—
1,201
—
Loss on the sale of business classified as held for sale
—
—
802
—
Adjusted income from operations
$ 202,992
$ 220,682
$ 762,938
$ 813,936
Income from operations margin
14.2 %
15.2 %
14.1 %
14.7 %
Adjusted income from operations margin
17.7 %
17.7 %
17.0 %
17.1 %
Reconciliation of Diluted EPS to Adjusted Diluted EPS11
(Per share data)
Three months ended
December 31,
Year ended
December 31,
2023
2024
2023
2024
Diluted EPS
$ 1.59
$ 0.79
$ 3.41
$ 2.85
Stock-based compensation expense
0.13
0.11
0.48
0.37
Amortization and impairment of acquired intangible assets
0.04
0.04
0.17
0.15
Restructuring (income) expense
—
—
(0.03)
—
Operating loss from the business classified as held for sale
—
—
0.01
—
Loss on the sale of business classified as held for sale
—
—
0.00
—
Tax impact on stock-based compensation expense
(0.01)
(0.02)
(0.10)
(0.05)
Tax impact on amortization and impairment of acquired intangible assets
(0.01)
(0.01)
(0.04)
(0.04)
Tax impact on restructuring (income) expense
—
—
0.01
—
Tax impact on operating loss from the business classified as held for sale
—
—
—
—
Tax benefit on intercompany transfer of intellectual property rights
(0.93)
—
(0.92)
—
Adjusted diluted EPS
$ 0.82
$ 0.91
$ 2.98
$ 3.28
11 Due to rounding, the numbers presented in this table may not add up precisely to the totals provided.
The following tables show the reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures for the year ending December 31, 2025:
Reconciliation of Outlook for Net Income Margin to Adjusted Income from Operations Margin12
Year ending December 31, 2025
Net income margin
10.7 %
Estimated interest (income) expense, net
1.0 %
Estimated income tax expense
3.5 %
Estimated stock-based compensation expense
1.6 %
Estimated amortization and impairment of acquired intangible assets
0.5 %
Adjusted income from operations margin
17.3 %
Reconciliation of Outlook for Income from Operations Margin to Adjusted Income from
Operations Margin12
Year ending December 31, 2025
Income from operations margin
14.9 %
Estimated stock-based compensation expense
1.6 %
Estimated amortization and impairment of acquired intangible assets
0.5 %
Estimated other income (expense), net
0.3 %
Adjusted income from operations margin
17.3 %
Reconciliation of Outlook for Diluted EPS to Adjusted Diluted EPS12
(Per share data)
Year ending December 31, 2025
Lower
Upper
Diluted EPS
$ 3.04
$ 3.11
Estimated stock-based compensation expense
0.46
0.46
Estimated amortization and impairment of acquired intangible assets
0.15
0.15
Estimated tax impact on stock-based compensation expense
(0.08)
(0.08)
Estimated tax impact on amortization and impairment of acquired intangible assets
(0.04)
(0.04)
Adjusted diluted EPS
$ 3.52
$ 3.59
12 Due to rounding, the numbers presented in this table may not add up precisely to the totals provided.
The following tables show the reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures for the quarter ending March 31, 2025:
Reconciliation of Outlook for Net Income Margin to Adjusted Income from Operations Margin13
Quarter ending March 31, 2025
Net income margin
10.1 %
Estimated interest (income) expense, net
1.1 %
Estimated income tax expense
3.3 %
Estimated stock-based compensation expense
1.5 %
Estimated amortization and impairment of acquired intangible assets
0.5 %
Adjusted income from operations margin
16.5 %
Reconciliation of Outlook for Income from Operations Margin to Adjusted Income from
Operations Margin13
Quarter ending March 31, 2025
Income from operations margin
14.1 %
Estimated stock-based compensation expense
1.5 %
Estimated amortization and impairment of acquired intangible assets
0.5 %
Estimated other income (expense), net
0.3 %
Adjusted income from operations margin
16.5 %
Reconciliation of Outlook for Diluted EPS to Adjusted Diluted EPS13
(Per share data)
Quarter ending March 31, 2025
Lower
Upper
Diluted EPS
$ 0.68
$ 0.69
Estimated stock-based compensation expense
0.10
0.10
Estimated amortization and impairment of acquired intangible assets
0.04
0.04
Estimated tax impact on stock-based compensation expense
(0.02)
(0.02)
Estimated tax impact on amortization and impairment of acquired intangible assets
(0.01)
(0.01)
Adjusted diluted EPS
$ 0.79
$ 0.80
13 Due to rounding, the numbers presented in this table may not add up precisely to the totals provided.
View original content to download multimedia:https://www.prnewswire.com/news-releases/genpact-reports-full-year-and-fourth-quarter-2024-results-302370628.html
SOURCE Genpact
You may like
Technology
Kidney Patients Back Bipartisan Bill to Expand Disability Employment
Published
25 minutes agoon
October 23, 2026By
U.S. Representatives Hoyer and Sessions Lead AbilityOne Modernization Bill
Kidney Disease and Jobs are Focus of National Disability Employment Month
WASHINGTON, Oct. 23, 2026 /PRNewswire/ — The American Association of Kidney Patients (AAKP), the nation’s oldest and largest independent kidney patient advocacy organization, today announced plans to accelerate national grassroots patient advocacy in support of bipartisan legislation that will modernize the federal AbilityOne program. The American Procurement Improvement Act (APIA), H.R. 10443, is championed by U.S. Representatives Pete Sessions (R-TX) and Steny Hoyer (D-MD). AAKP defines kidney disease as both an American healthcare and workforce issue and fights to expand career opportunities and job protections for all Americans impacted by kidney disease, disabilities, and chronic diseases.
The AbilityOne program creates private sector employment opportunities for over 41,000 Americans with severe vision and other disabilities, including nearly 3,000 American Veterans. In FY 2025, the program generated nearly 48 million direct labor hours, an 8 percent increase and a significant measure of disability employment growth, with workers working and working more hours. AbilityOne delivered more than $4.7 billion in products and services to the Federal government in FY 2025 and drew discouraged workers into the U.S. labor force while supporting greater workforce participation, increasing economic independence, and self-sufficiency. The AbilityOne mission taps the underutilized workforce of people with significant disabilities to deliver high-quality, mission-essential products and services to federal agencies, including the U.S. Department of Defense and the U.S. Department of Homeland Security.
The APIA legislation removes outdated statutory barriers to hiring, retention, advancement, and movement into careers of choice, including emerging fields and new lines of business. It also modernizes federal procurement by aligning AbilityOne with contemporary procurement practices and streamlines procurement processes so the program can respond faster to emerging federal agency priorities. The APIA legislation protects taxpayer interests, strengthens program accountability and stewardship by preserving oversight, transparency, and worker protections while modernizing AbilityOne Commission authorities. The legislation is seen as an opportunity to improve federal procurement and strengthen the federal government’s domestic supplier base.
Over 36 million Americans live with kidney disease, over 600,000 are on dialysis, and nearly 100,000 are awaiting a kidney transplant. Further, interrelated cardiovascular, kidney, and metabolic diseases have impacted more than 25% of the adult population and are a leading cause of death. More broadly, the American Heart Association estimates that 90% of U.S. adults, or about 240 million people, have some degree of interconnected cardiovascular, kidney, or metabolic health conditions. For kidney patients dependent upon status-quo, in-center hemodialysis, burdensome thrice-weekly dialysis sessions force many patients, against their own choosing, into unemployment, disability, and dependency. AAKP believes dialysis-related unemployment, and the associated costs borne by families and taxpayers, is one of the media’s least-reported stories in legacy kidney care. AAKP’s policy agenda focuses on transplant readiness, more opportunities for organ transplants, more flexible, patient-centered home dialysis solutions, and stronger job protections for both kidney patients and living organ donors.
AAKP President Edward V. Hickey, III, a chronic kidney disease patient, stated, “AAKP strongly endorses the American Procurement Improvement Act (APIA) and expresses our deepest gratitude to Representatives Steny Hoyer and Peter Sessions for their bipartisan leadership and commitment to Americans managing disabilities and their efforts to secure meaningful employment opportunities with solid wages. People impacted by disability and chronic diseases face tremendous hurdles to continued employment and return to the workforce – especially America’s proud Veterans. This legislation reflects consensus language among stakeholders, including advocates, employers, and organized labor, and sends a very positive message, amid national economic concerns, that the voices and needs of disabled Americans and their families are heard and not forgotten by the U.S. Congress. We encourage Congress to step up and pass this legislation before the close of the year.” Hickey is a U.S. Marine Corps Veteran, a former senior congressional aide, and has served in appointed roles in two presidential administrations, including the U.S. Department of Commerce (DOC) and the U.S. Office of Personnel Management (OPM). At OPM, he was heavily involved in policy issues related to federal Veterans preference in civil service hiring and expanded federal job opportunities. He currently serves on the American Board of Internal Medicine’s (ABIM) Nephrology Specialty Board and as the Chair of the AAKP Veterans Health Initiative, the largest kidney health outreach program outside of the U.S. Department of Veterans Affairs.
October is National Disability Employment Month, and AAKP and its allies remind elected and appointed government leaders to address health and employment concerns that impact patients, families, and communities. Through multiple partnerships, AAKP leads the kidney community in providing kidney patients and transplant recipients, including Veterans, access to virtual job fairs and employment skills training opportunities. AAKP is currently sponsoring virtual job fairs, in partnership with CareerEco, on January 13, 2027, and May 18, 2027, that will service Veterans and military families. AAKP’s past collaborations have included webinars with Idealist and virtual disability and Veteran hiring fairs with Bender Consulting.
AAKP Vice President and Chair of Policy and Global Affairs Paul T. Conway, a 49-year kidney patient and 29-year transplant recipient, stated, “The AbilityOne program has supported private sector employment for people managing disabilities and chronic diseases for nearly ninety years and reflects the exceptional American values of self-reliance and independence. Representatives Steny Hoyer and Pete Sessions have consistently shown respect for the creativity, talents, and skills of disabled citizens and have dedicated their public careers to expanding job opportunities in the workforce and across the federal supply chain. The American Procurement Improvement Act increases accountability for taxpayer funds and will result in more well-paying jobs for Americans whose desire and capacity to work and contribute are underappreciated.” Conway is a former Chief of Staff for both the U.S. Department of Labor and the U.S. Office of Personnel Management and a former Deputy Secretary for Health and Human Resources for the Commonwealth of Virginia. He has overseen multiple federal and state disability employment, workforce training, and health service programs throughout his public career. He is the past Chair of the U.S. Food and Drug Administration’s Patient Engagement Advisory Committee (PEAC) and serves on the Observational Study Monitoring Board of the Kidney Precision Medicine Program (KPMP) administered by the National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases (NIH/NIDDK).
To advance the APIA, AAKP is working with former U.S. Representative Tony Coelho, Chair of the Partnership to Improve Patient Care as well as the Alliance for Expanding America’s Workforce. Along with AAKP, APIA is endorsed by over 60 national patient and disability organizations, labor unions and employers including the American Association of People with Disabilities, SEIU, Bender Consulting, National Council of SourceAmerica Employers, CEO Commission for Disability Employment, the Arc of the United States, National Organization on Disability, National Down Syndrome Society, National Disability Rights Network, National Federation of the Blind, Melwood Inc., WORK Inc., ORC Industries, Employment Source, Opportunity Center, Inc., PARC, ACHIEVE Human Services, Inc., Human Technologies, InspiriTec, PORTCO Inc, PRIDE Industries, Phoenix, Pueblo Diversified Industries, and the Association of People Supporting EmploymentFirst (APSE).
AAKP, alongside a broad and diverse coalition of patient organizations, transplant experts, and Congressional allies, is also working to secure passage of the Living Donor Protection Act (LDPA), S. 1552/H.R. 4582 and H.R. 4583, in 2026. The bipartisan bill protects living organ donors from job and insurance discrimination based solely on their decision to donate a kidney to save another life, barriers cited most often by potential organ donors. The bipartisan legislation is led by Senator Tom Cotton (R-AK) and Senator Kirsten Gillibrand (D-NY). It was voted out of the Senate HELP Committee on February 26, 2026, with full bipartisan support, the endorsement of AAKP, the larger kidney community, and the American Council of Life Insurance (ACLI).
In 2018, with bipartisan support from Congress and the Trump Administration, AAKP and transplant professionals worked with the U.S. Department of Labor’s (DOL) legal team and the DOL Wage and Hour Division to have DOL issue Family and Medical Leave Act (FMLA) protections for living organ donors, based on the original intent of the FMLA’s Congressional co-sponsors (click here to read the letter and click here to watch the video). Congressional passage of the LDPA in 2026 will codify the DOL’s 2018 FMLA job protections and prohibit insurers from discriminating against living donors. Increased living organ donation, improved transplant readiness among kidney patients, and greater opportunities for transplantation have been national goals for decades and were reinforced in 2019 through the Executive Order on Advancing American Kidney Health.
Follow AAKP on social media at @kidneypatient on Facebook, @kidneypatients on X, and @kidneypatients on Instagram, and visit https://aakp.org/ for more information. AAKP patient advocates advance bipartisan kidney policy including: passage of the bipartisan law modernizing the Organ Procurement and Transplantation Network (OPTN) (2023); lifetime transplant drug coverage for kidney patients (2020); the historic Executive Order on Advancing American Kidney Health signed by President Donald Trump (2019); job protections for living organ donors under the Family Medical Leave Act (FMLA) via the U.S. Department of Labor (2018); and Congressional approval of HIV positive organ transplants for HIV positive patients (2013).
MEDIA CONTACT:
Brendan LaCivita
National and Medical Media Specialist
blacivita@aakp.org
(813) 906-7740
View original content to download multimedia:https://www.prnewswire.com/news-releases/kidney-patients-back-bipartisan-bill-to-expand-disability-employment-302918393.html
SOURCE American Association of Kidney Patients
Technology
BioVid Launches Mimetics™, AI Research Audiences Built on How Physicians Reason and Decide
Published
25 minutes agoon
October 23, 2026By
Modeling physician response patterns and behavior, showing an 80–90% match with real physicians on content, reasoning, and emotion.
BRISTOL, Pa., Oct. 23, 2026 /PRNewswire/ — BioVid, a life science consultancy, today announced the launch of BioVid Mimetics™, a research platform that gives pharmaceutical teams mimetics: synthetic physician audiences modeled on how those audiences reason and decide. Its respondent models are grounded in BioVid’s proprietary MindSet Modeling™ program, large-scale, multi-specialty surveys of practicing physicians that measure the mindsets shaping how they process information, make judgments, and decide. The models are aligned with secondary data on clinical practice, moving beyond generic AI role-play to model the decision logic behind treatment choices.
Prescribing data shows what physicians choose, not why. Pharma teams now face more of those “why” questions than research budgets and timelines can absorb. BioVid Mimetics™ applies the social and behavioral science of clinical judgment to model how physicians interpret evidence, weigh benefit against risk, and decide when they know enough to act.
The name comes from pharmacology, where a mimetic earns trust by doing the work of the original molecule. Every BioVid mimetic is tested against that standard, bringing the firm’s long-standing commitment to science-based research to a new method.
“At BioVid, we’ve always believed that better commercial decisions start with a deeper understanding of human behavior,” said Peggy Hirtle, CEO of BioVid. “Our goal was never simply faster or cheaper respondents. It was to reflect how physicians actually reason, with the same scientific rigor clients already trust from BioVid. Mimetics is a new way to put human understanding to work, never a replacement for it.”
“A synthetic respondent can sound right and still reason wrong. The real test is whether it reasons the way the audience does,” said Marco Barcella, Executive Director, Product & Technology at BioVid. “Where the decision warrants, we run the same study with a human cohort and a mimetic cohort and compare the findings, the reasoning, and the mental and emotional responses directly. Clients see where mimetic findings hold and where human research should lead.”
In BioVid’s validation work to date, mimetic and human cohorts have shown an 80% to 90% match on content, reasoning, and emotion across thousands of parallel tests.
BioVid Mimetics™ is available off the shelf or tailored with a client’s own primary research. It supports message and concept testing, positioning, drivers and barriers, segmentation, and opportunity assessment, and includes:
Mimetic Respondents: Mimetic or hybrid studies, with mimetic fieldwork complete in one to two weeks after receipt of required inputs, followed by a full report and readout from BioVid’s research team.
Mimetic Segments App: Segments that client teams question directly, share materials with, and return to between research waves.
Client Customization: Models tailored with a client’s own research, segment profiles, and CRM data, exclusive to that client and firewalled from all others.
To learn more, visit www.biovid.com/mimetics.
About BioVid
BioVid is a life science consultancy applying behavioral science and AI to commercial and market access strategy. Its offerings include the CIAIRA™ AI platform, Tumor Worlds™, and BioVid Mimetics™. BioVid is a recognized leader in new product demand estimation, commercial communication optimization, and customer and patient segmentation research.
Visit www.biovid.com.
Media Contact:
Sal Zerilli, PhD, Executive Director, Knowledge and Innovation, BioVid
szerilli@biovid.com | 267.201.4008
View original content to download multimedia:https://www.prnewswire.com/news-releases/biovid-launches-mimetics-ai-research-audiences-built-on-how-physicians-reason-and-decide-302918401.html
SOURCE BioVid
Technology
Egan-Jones Finds Steady CLO Credit Metrics as Interest Rates Turn Higher
Published
25 minutes agoon
October 23, 2026By
NEW YORK, Oct. 23, 2026 /PRNewswire/ — Egan-Jones released its monthly report on the collateralized loan obligation (CLO) market, finding that credit metrics across the deals it rates held steady even as interest rates and high-yield spreads moved higher in September. For investors, the publication sets these steadier portfolio measures against a tighter rate backdrop.
Among Egan-Jones’ measures, the weighted average rating score, a gauge of the default risk in a deal’s underlying loans where a lower score indicates stronger credit, has improved over the past year. The share of assets rated CCC+ or lower, the weakest tier of loan ratings, has been stable to slightly lower, with a median of 6.1%. As of September 2026, Egan-Jones rated 1,568 CLO deals.
The steadier metrics come as financing conditions shift. The 5-year Treasury yield rose 60 basis points to 5.09%, its highest close of 2026, and on September 16 the Federal Reserve raised rates by 25 basis points, its first increase since 2023. High-yield spreads widened to 312 basis points from their late-August low, while new CLO issuance totaled 91 deals ($38.2 billion), down 12.5% by count from a year earlier.
Higher rates cut both ways for CLOs, according to the analysis: coupons on the underlying loans reset upward, but so do the interest burdens of the borrowers. Egan-Jones points to rising loss severity on distressed exchanges and other selective defaults, and identifies software loans, pressured by concerns over disruption from artificial intelligence, as the weakest sector in CLO portfolios.
Egan-Jones also compares its ratings with those of other agencies across 20 deals, ranking the tranches where views differ most. On that comparison, Egan-Jones currently tends to take a more positive view of CLO credit quality than other credit rating agencies. A full sample rating report on MP CLO VIII, whose largest industry exposure is High Tech Industries at 15.9%, is included.
Taken together, the findings describe a market in which issuance has eased and borrowing costs are rising, while the credit profile of Egan-Jones-rated portfolios remains stable. Watching where pressures such as software exposure and loss severity are building may help investors assess CLO risk as the rate cycle turns.
About Egan-Jones Ratings
Egan-Jones, an NRSRO founded in 1995, offers timely and accurate credit ratings and proxy services.
Media Contact:
sales@egan-jones.com
+1 212 425 0460
View original content to download multimedia:https://www.prnewswire.com/news-releases/egan-jones-finds-steady-clo-credit-metrics-as-interest-rates-turn-higher-302918341.html
SOURCE Egan-Jones Ratings Co.
Kidney Patients Back Bipartisan Bill to Expand Disability Employment
BioVid Launches Mimetics™, AI Research Audiences Built on How Physicians Reason and Decide
Egan-Jones Finds Steady CLO Credit Metrics as Interest Rates Turn Higher
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology5 days agoGMIF2026: AI Inference Powers the “Token Factory” and Drives System-Level Rethinking of Memory & Storage
-
Technology4 days agoInstaMall Launches Same-Day Fashion Delivery Experience, Bringing 80+ Brands to Shoppers’ Doors in Miami
-
Technology5 days agoHISTOINDEX AND A*STAR PARTNER TO ADVANCE EARLY-STAGE DEVELOPMENT OF PIPELINE THERAPIES FOR FIBROTIC DISEASES
-
Coin Market4 days agoWorld Liberty’s USD1 stablecoin sheds $400M in market cap in two weeks
-
Technology5 days agoTruecaller announces preliminary numbers for the third quarter 2026
-
Technology5 days agoTrend Micro Announces Up to ¥10 Billion toward Cyber Resilience Initiative to Strengthen Security for Japanese Organizations in the AI Era
-
Technology5 days agoSALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
-
Technology4 days agoTreasuries Rallied as Tech Slid, and the Crowded Bet Against Bonds Felt It